grepcent public filings, reorganized for comparison

ALDORIL 15 / ALDORIL 25 / ALDORIL D30 / ALDORIL D50 — FDA application NDA013402

Application NDA013402 · type NDA · FDA status: approved · original approval 1962-12-20

Listed sponsor: MERCK · MRK company profile · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

FDA application facts

ProductFDA-listed trade nameActive ingredientDosage formRouteStrengthMarketing statusTE codeRLD
001ALDORIL 15HYDROCHLOROTHIAZIDE; METHYLDOPATABLETORAL15MG;250MGDiscontinuednot listedNo
002ALDORIL 25HYDROCHLOROTHIAZIDE; METHYLDOPATABLETORAL25MG;250MGDiscontinuednot listedNo
003ALDORIL D30HYDROCHLOROTHIAZIDE; METHYLDOPATABLETORAL30MG;500MGDiscontinuednot listedNo
004ALDORIL D50HYDROCHLOROTHIAZIDE; METHYLDOPATABLETORAL50MG;500MGDiscontinuednot listedNo

Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.

Orange Book patent and exclusivity listings

No Orange Book patent or exclusivity listings joined to this application.

Compound cross-links

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

Related pages

Sponsor company · FDA-approved application index

Peer clusters: Large-cap biopharma

Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.